| Lysosomal Storage Disease |
0 |
0.65 |
| Food and Drug Administration (FDA) |
0 |
1 |
| Glycogen Storage Disease (GSD) Type II |
0 |
0.57 |
| Urticaria and Angioedema |
0 |
0.34 |
| Dermatitis |
0 |
0.33 |
| Anaphylaxis |
0 |
0.3 |
| Id Reaction |
0 |
0.29 |
| Intravenous |
0 |
0.29 |
| Myalgia |
0 |
0.26 |
| Pain Management |
0 |
0.22 |
| Muscle |
0 |
0.19 |
| Rare Diseases |
0 |
0.8 |
| Patient Safety |
0 |
0.18 |
| Heart Failure (HF) |
0 |
0.15 |
| Arthralgia |
0 |
0.14 |
| Diarrhea |
0 |
0.11 |
| Headache |
0 |
0.11 |
| Social Determinants of Health |
0 |
0.11 |
| Adverse Effects |
0 |
0.1 |
| Birth |
0 |
0.1 |
| Dizziness |
0 |
0.1 |
| Dyspnea |
0 |
0.1 |
| Emesis |
0 |
0.1 |
| Fatigue |
0 |
0.1 |
| Fever |
0 |
0.1 |
| Grant |
0 |
0.1 |
| Health Care Quality, Access, and Evaluation |
0 |
0.1 |
| Heart |
0 |
0.1 |
| Nausea |
0 |
0.1 |
| Orphan Drugs |
0 |
0.1 |
| Pain |
0 |
0.1 |
| Paresthesia |
0 |
0.1 |
| Pruritus |
0 |
0.1 |
| Reproductive Medicine |
0 |
0.1 |
| Respiratory Failure |
0 |
0.1 |
| Urticaria |
0 |
0.1 |
| Weakness |
0 |
0.1 |